At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34 enrolled
Drug / intervention
saline 0.9% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial of the Effect of Liposomal Bupivacaine (Exparel) When Compared to Saline Control in Reducing Opioid Utilization for Pain Management in Postoperative Lumbar Spine Surgeries.
In Brief
A Phase 4 clinical trial evaluating saline 0.9% and Liposomal bupivacaine for Lumbar Spine Degeneration. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to establish a relationship between liposomal bupivacaine surgical site injection and postop opioid utilization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLumbar Spine Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartFeb 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedNov 25, 2020
Enrollment StartFeb 10, 2021
Primary CompletionJun 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.6 years ago
Interventions
saline 0.9%drug
Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
Liposomal bupivacainedrug
Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.